JP2012111764A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012111764A5 JP2012111764A5 JP2012001451A JP2012001451A JP2012111764A5 JP 2012111764 A5 JP2012111764 A5 JP 2012111764A5 JP 2012001451 A JP2012001451 A JP 2012001451A JP 2012001451 A JP2012001451 A JP 2012001451A JP 2012111764 A5 JP2012111764 A5 JP 2012111764A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- administered
- subject
- plasma concentration
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 230000036470 plasma concentration Effects 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 102000009346 Adenosine receptors Human genes 0.000 claims 4
- 108050000203 Adenosine receptors Proteins 0.000 claims 4
- AJACDNCVEGIBNA-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-amino-2-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C12=NC(OC)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O AJACDNCVEGIBNA-KQYNXXCUSA-N 0.000 claims 2
- AJACDNCVEGIBNA-UHFFFAOYSA-N 2-Methoxyadenosine Natural products C12=NC(OC)=NC(N)=C2N=CN1C1OC(CO)C(O)C1O AJACDNCVEGIBNA-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000001953 Hypotension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000007101 Muscle Cramp Diseases 0.000 claims 2
- 206010049565 Muscle fatigue Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 208000005392 Spasm Diseases 0.000 claims 2
- 208000001871 Tachycardia Diseases 0.000 claims 2
- 230000036471 bradycardia Effects 0.000 claims 2
- 208000006218 bradycardia Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 230000036543 hypotension Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 230000006794 tachycardia Effects 0.000 claims 2
- RROANHICBKIZLM-QYVSTXNMSA-N (2r,3r,4s,5r)-2-(6-amino-2-butoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C12=NC(OCCCC)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RROANHICBKIZLM-QYVSTXNMSA-N 0.000 claims 1
- NFMJXEMKAVCGPF-IOSLPCCCSA-N (2r,3r,4s,5r)-2-(6-amino-2-ethoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C12=NC(OCC)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NFMJXEMKAVCGPF-IOSLPCCCSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0305150.5 | 2003-03-07 | ||
| GBGB0305150.5A GB0305150D0 (en) | 2003-03-07 | 2003-03-07 | Use of therapeutic compounds |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006505924A Division JP2006519824A (ja) | 2003-03-07 | 2004-03-05 | アデノシン受容体アゴニストの治療上の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012111764A JP2012111764A (ja) | 2012-06-14 |
| JP2012111764A5 true JP2012111764A5 (OSRAM) | 2013-04-18 |
Family
ID=9954248
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006505924A Ceased JP2006519824A (ja) | 2003-03-07 | 2004-03-05 | アデノシン受容体アゴニストの治療上の使用 |
| JP2012001451A Pending JP2012111764A (ja) | 2003-03-07 | 2012-01-06 | アデノシン受容体アゴニストの治療上の使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006505924A Ceased JP2006519824A (ja) | 2003-03-07 | 2004-03-05 | アデノシン受容体アゴニストの治療上の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7790698B2 (OSRAM) |
| EP (1) | EP1603576A1 (OSRAM) |
| JP (2) | JP2006519824A (OSRAM) |
| KR (1) | KR20050115895A (OSRAM) |
| CN (2) | CN1809365A (OSRAM) |
| AU (1) | AU2004216891B2 (OSRAM) |
| CA (1) | CA2514848A1 (OSRAM) |
| GB (1) | GB0305150D0 (OSRAM) |
| NO (1) | NO20054475L (OSRAM) |
| NZ (1) | NZ541587A (OSRAM) |
| WO (1) | WO2004078184A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0228723D0 (en) | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
| GB0305153D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Identification of therapeutic compounds |
| GB0305150D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Use of therapeutic compounds |
| KR20070004792A (ko) * | 2004-03-05 | 2007-01-09 | 캠브리지 바이오테크놀로지 리미티드 | 아데노신 수용체 작용제 |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| MX2007005525A (es) * | 2004-11-08 | 2007-07-05 | Can Fite Biopharma Ltd | Tratamiento terapeutico de resorcion ose acelerada. |
| AU2006204699B2 (en) * | 2005-01-13 | 2012-04-26 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| BRPI0619395A2 (pt) | 2005-11-30 | 2011-10-04 | Can Fite Biopharma Ltd | uso de um agonista de receptor de adenosina a3(a3ar) |
| JP2009541438A (ja) | 2006-06-27 | 2009-11-26 | ビオヴィトルム・アクチボラゲット（プブリクト） | 治療用化合物 |
| JP2009541437A (ja) | 2006-06-27 | 2009-11-26 | ビオヴィトルム・アクチボラゲット（プブリクト） | 治療用化合物 |
| ES2361886T3 (es) | 2006-06-27 | 2011-06-24 | Cbt Development Limited | Profármacos adenosina acetil 2',3'-metilideno novedosos para uso como profármacos para agonistas del receptor adenosina. |
| WO2011004166A1 (en) * | 2009-07-09 | 2011-01-13 | Cbt Development Limited | Combined preparation for use as a medicament |
| CN101947230B (zh) * | 2010-08-25 | 2012-10-10 | 苗志敏 | 5’-amp用于治疗痛风性关节炎的用途 |
| CN103342727A (zh) * | 2013-07-01 | 2013-10-09 | 淮海工学院 | 一种2-甲氧基腺苷的合成方法 |
| CN108329372B (zh) * | 2017-01-20 | 2022-07-26 | 浙江省亚热带作物研究所 | N6-(2-羟乙基)腺苷及其衍生物在制备治疗痛风药物中的应用 |
| JP7025129B2 (ja) * | 2017-05-17 | 2022-02-24 | 小林製薬株式会社 | 筋痙攣治療剤 |
| US20220218712A1 (en) * | 2019-02-25 | 2022-07-14 | Saint Louis University | Treatment of alzheimer's disease |
| JPWO2022050230A1 (OSRAM) * | 2020-09-03 | 2022-03-10 | ||
| CN113116900B (zh) * | 2021-04-14 | 2022-07-08 | 兰州大学 | 一类核苷类似物在制备预防和/或治疗脑血管疾病药物中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4861498A (OSRAM) | 1971-12-01 | 1973-08-28 | ||
| BE792155A (fr) | 1971-12-01 | 1973-05-30 | Takeda Chemical Industries Ltd | Nouveaux derives de l'adenosine et leur procede de production |
| DE2359536C2 (de) | 1972-12-08 | 1984-08-02 | Takeda Chemical Industries, Ltd., Osaka | 2,6-Diaminonebularinderivate |
| JPS5461194A (en) | 1977-10-21 | 1979-05-17 | Takeda Chem Ind Ltd | Preparation of n22substituted 2*66diaminonebularin |
| JPS5461195A (en) | 1977-10-21 | 1979-05-17 | Takeda Chem Ind Ltd | N2-substituted phenyl-2,6-diaminonebularin |
| US4705758A (en) | 1984-06-19 | 1987-11-10 | Warner-Lambert Company | Adenosine receptor assay and kit |
| US5104859A (en) * | 1985-09-24 | 1992-04-14 | Solimedco Aktiebolag | Continuous administration of adenosine to reduce pulmonary vascular resistance |
| US5231086A (en) * | 1985-09-24 | 1993-07-27 | Item Development Aktiebolag | Continuous administration adenosine to increase myocardial blood flow |
| US5679650A (en) * | 1993-11-24 | 1997-10-21 | Fukunaga; Atsuo F. | Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine |
| US6180616B1 (en) * | 1990-05-10 | 2001-01-30 | Atsuo F. Fukunaga | Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function |
| US6004945A (en) * | 1990-05-10 | 1999-12-21 | Fukunaga; Atsuo F. | Use of adenosine compounds to relieve pain |
| US5677290A (en) * | 1990-05-10 | 1997-10-14 | Fukunaga; Atsuo F. | Therapeutic use of adenosine compounds as surgical anesthetics |
| US5683989A (en) * | 1993-12-17 | 1997-11-04 | Novo Nordisk A/S | Treatment of ischemias by administration of 2,N6 -substituted adenosines |
| US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
| IT1275420B (it) | 1995-06-02 | 1997-08-05 | Schering Plough S P A | Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261 |
| CA2317093A1 (en) | 1998-01-08 | 1999-07-15 | Joel M. Linden | A2a adenosine receptor agonists |
| US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| GB0305149D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
| GB0305153D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Identification of therapeutic compounds |
| GB0305150D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Use of therapeutic compounds |
-
2003
- 2003-03-07 GB GBGB0305150.5A patent/GB0305150D0/en not_active Ceased
-
2004
- 2004-03-05 CN CNA2004800057235A patent/CN1809365A/zh active Pending
- 2004-03-05 AU AU2004216891A patent/AU2004216891B2/en not_active Ceased
- 2004-03-05 CA CA002514848A patent/CA2514848A1/en not_active Abandoned
- 2004-03-05 JP JP2006505924A patent/JP2006519824A/ja not_active Ceased
- 2004-03-05 US US10/547,454 patent/US7790698B2/en not_active Expired - Fee Related
- 2004-03-05 KR KR1020057016713A patent/KR20050115895A/ko not_active Ceased
- 2004-03-05 CN CN201010524262XA patent/CN102058614A/zh active Pending
- 2004-03-05 NZ NZ541587A patent/NZ541587A/en unknown
- 2004-03-05 WO PCT/GB2004/000952 patent/WO2004078184A1/en not_active Ceased
- 2004-03-05 EP EP04717693A patent/EP1603576A1/en not_active Withdrawn
-
2005
- 2005-09-27 NO NO20054475A patent/NO20054475L/no not_active Application Discontinuation
-
2010
- 2010-09-02 US US12/875,035 patent/US20110166093A1/en not_active Abandoned
-
2012
- 2012-01-06 JP JP2012001451A patent/JP2012111764A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012111764A5 (OSRAM) | ||
| JP2013542247A5 (OSRAM) | ||
| NZ732507A (en) | Improved compositions for treating muscular dystrophy | |
| FI3287124T3 (fi) | Ketamiinin oraalinen annosmuoto | |
| RU2015107877A (ru) | Способы лечения болезни альцгеймера и фармацевтические композиции | |
| JP2013507415A5 (OSRAM) | ||
| FI4406594T3 (fi) | Kilpirauhashormonin analogeja | |
| MX2017011836A (es) | Terapia de combinacion optimizada y uso de la misma para tratar cancer y enfermedad autoinmunitaria. | |
| JP2013545730A5 (OSRAM) | ||
| JP2012530779A5 (OSRAM) | ||
| WO2013158680A3 (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| JP2013505205A5 (OSRAM) | ||
| JP2011505356A5 (OSRAM) | ||
| JP2014516942A5 (OSRAM) | ||
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| MX354423B (es) | Formulaciones de rasagilina de liberación prolongada y usos de las mismas. | |
| SI3137081T1 (en) | BUPRENORFIN DIMER AND ITS USE IN HEALTHY DISEASE DISEASES | |
| WO2012142615A3 (en) | Auranofin and auranofin analogs useful to treat proliferative disease and disorders | |
| JP2014513065A5 (OSRAM) | ||
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| JP2014530181A5 (OSRAM) | ||
| JP2018524306A5 (OSRAM) | ||
| JP2014530204A5 (OSRAM) | ||
| JP2016512247A5 (OSRAM) | ||
| FI3352735T3 (fi) | Pitkitetysti vapauttavia olantsapiiniformulaatioita |